Driving Innovation in Nuclear Medicine Imaging: Exploring Market Trends and Opportunities
While many nuclear medicine imaging modalities can quantitively measure how radiopharmaceuticals interact with living tissues, few have the resolution necessary to zoom down to level of single cells,” said Guillem Pratx, PhD, associate professor of radiation oncology at Stanford University in Stanford, California. “This potentially hinders the development of effective radiopharmaceuticals for disease detection, staging, and treatment.
?????? ???????? ??????????????- https://www.marketinsightsreports.com/reports/100313031989/global-nuclear-medicine-imaging-system-market-growth-status-and-outlook-2023-2029/inquiry?mode=126
To address this issue, researchers constructed a compact instrument that images radiopharmaceuticals by direct detection of ionizing charged particles via a consumer-grade complementary metal-oxide semiconductor detector. It is made from off-the-shelf parts that cost less than $100, which is approximately 500 times less than the radioluminescence microscope, the closest imaging device to the lensless microscope.
Upon proof-of-concept testing, the lensless radiomicroscope produced high-resolution images of more than 5,000 cells within its 1 cm2?field of view, a hundredfold increase over current state-of-the-art technology. Static and dynamic images were successfully created for both beta- and alpha-emitting radionuclides with the lensless radiomicroscope.
ADAC Laboratories is a worldwide market leader in nuclear medicine imaging equipment and radiation therapy planning systems. The company offers a broad range of nuclear medicine systems that are used primarily in the diagnosis of heart disease and cancer. In addition, ADAC Laboratories is an emerging leader in positron emission tomography (PET) imaging. PET provides physicians with solutions for accurate cancer disease management. The market for PET systems has grown dramatically in the past year due to expanded Medicare reimbursement, and the widespread acceptance of PET in the U.S.A. for cancer diagnosis, staging and treatment follow-up.